The olfactory bulb – gateway for SARS-Cov-2?
Abstract
Introduction. Anosmia and ageusia are one of the most common and characteristic symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, with a frequency of almost 50% in patients in Western countries. Hypotheses proposing that the virus potentially affects the central nervous system (CNS) are on the rise. One hypothesis suggests that the virus enters via nasal mucosa and then enters the olfactory bulb via cribriform plate, with further dissemination to the CNS. Case report. A 34-year-old female patient experienced the loss of the sense of smell and taste about two months before testing positive for SARS-Cov-2. Coronavirus disease 2019 (COVID-19) presented with minor pneumonia and worsening anosmia and ageusia. After treatment, the patient recovered well, but anosmia and ageusia appeared again, varying in intensity, and since February 2021, they have become persistent. The case was evaluated by an otorhinolaryngologist, pulmonologist, and finally, a neurologist. In the meantime, the patient tested negative for SARS-Cov-2 and received two doses of the Sputnik V vaccine. Brain magnetic resonance imaging (MRI) was performed, and it clearly showed severe bilateral olfactory bulb atrophy. The patient has had anosmia and ageusia up to this day, and future MRI follow-up is planned. Conclusion. Loss of sense of smell and taste may be a predictor of further CNS dissemination of the virus and possible neurological complications (which is still a subject of consideration). The olfactory bulb could be a gateway to COVID-19 intrusion into the CNS, and its atrophy could be an indicator of the process. Further investigation on this topic is required, including a wide application of MRI, in order to come to definite conclusions.
References
Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA 2020; 323(20): 2089‒90
Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. Laryngo-scope 2020; 130(7): 1787.
Sashindranath M, Nandurkar HH. Setting the Stage for Stroke and Other Cerebrovascular Complications of COVID-19. Stroke 2021; 52(2): 1895–904.
Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory dysfunction and sinonasal sympto-matology in COVID-19: prevalence, severity, timing, and as-sociated characteristics. Otolaryngol Head Neck Surg 2020; 163(1): 114‒20.
Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med 2020; 25(5): 471–8.
Duprez TP, Rombaux P. Imaging the olfactory tract (cranial nerve #1). Eur J Radiol 2010; 74(2): 288‒98.
Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, et al. Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2. J Med Virol 2020; 92(6): 602‒11.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus dis-ease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683–90.
Gupta K, Mohanty SK, Mittal A, Kalra S, Kumar S, Mishra T, et al. The Cellular basis of loss of smell in 2019-nCoV-infected individuals. Brief Bioinform 2021; 22(2): 873‒81.
Mostafa-Hedeab G. ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review. Rep Biochem Mol Biol 2020; 9(1): 97–105.
De Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithe-lium and brain infection in hamsters. Sci Transl Med 2021; 13(596): eabf8396.
Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist 2021; 27(6): 582‒603.
Bilinska K, Jakubowska P, von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci 2020; 11(11): 1555–62.
Chiu A, Fischbein N, Wintermark M, Zaharchuk G, Yun PT, Ze-ineh M. COVID-19-induced anosmia associated with olfactory bulb atrophy. Neuroradiology 2021; 63(1): 147‒8.
Shor N, Chougar L, Pyatigorskaya N. MR Imaging of the Olfac-tory Bulbs in Patients with COVID-19 and Anosmia: How to Avoid Misinterpretation. AJNR Am J Neuroradiol 2021; 42(3): E10‒E11.
Galougahi MD, Ghorbani J, Bakhshayeshkaram M, Naeini AS, Haseli S. Olfactory bulb magnetic resonance imaging in SARS-Co-V-2 induced anosmia: the first report. Acad Radiol 2020; 27(2): 892‒3.
Liang YC, Tsai YS, Syue LS, Lee NY, Li CW. Olfactory Bulb Atrophy in a Case of COVID-19 with Hyposmia. Acad Radiol 2020; 27(11): 1649–50.
Las Casas Lima MH, Cavalcante ALB, Leão SC. Pathophysio-logical relationship between COVID-19 and olfactory dys-function: A systematic review. Braz J Otorhinolaryngol 2021: S1808-8694(21)00073-2.
Tsivgoulis G, Fragkou PC, Lachanis S, Palaiodimou L, Lambadiari V, Papathanasiou M, et al. Olfactory bulb and mucosa abnor-malities in persistent COVID-19-induced anosmia: a magnetic resonance imaging study. Eur J Neurol 2021; 28(1): e6-e8.
Xydakis MS, Albers MW, Holbrook EH, Lyon DM, Shih RY, Frasnelli JA, et al. Post-viral effects of COVID-19 in the ol-factory system and their implications. Lancet Neurol 2021; 20(9): 753–61.
Renaud M, Thibault C, Le Normand F, Mcdonald EG, Gallix B, Debry C, et al. Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis. JAMA Netw Open 2021; 4(6): e2115352.
Thomann PA, Dos Santos V, Toro P, Schönknecht P, Essig M, Schröder J. Reduced olfactory bulb and tract volume in early Alzheimer's disease-a MRI study. Neurobiol Aging 2009; 30(5): 838‒41.
Huisman E, Uylings HBM, Hoogland PV. Gender-related chang-es in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov Disord 2008; 23(10): 1407–13.
Wattendorf E, Welge-Lüssen A, Fiedler K, Bilecen D, Wolfensberger M, Fuhr P, Hummel et al. Olfactory Impairment Predicts Brain Atrophy in Parkinson's Disease. J Neurosci. 2009; 29(49): 15410–3.
Lechien JR, Diallo AO, Dachy B, Le Bon SD, Maniaci A, Vaira LA, et al. COVID-19: Post-vaccine Smell and Taste Disor-ders: Report of 6 Cases. Ear Nose Throat J 2021; 1455613211033125.
Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. Int J Mol Sci 2020; 21(16): 5807.
Sorokowska A, Drechsler E, Karwowski , Hummel T. Effects of olfactory training: a meta-analysis. Rhinology 2017; 55(1): 17‒26.
Liu DT, Sabha M, Damm M, Philpott C, Oleszkiewicz A, Hähner A, et al. Parosmia is Associated with Relevant Olfactory Re-covery After Olfactory Training. Laryngoscope 2021; 131(3): 618‒23.
Zhang Y, Mei T, Chen Y, Wang L, Jiang L, Liu K, et al. Smell disorders in COVID-19 patients: role of olfactory training: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100(8): e24862.
Kortela E, Kirjavainen V, Ahava MJ, Jokiranta ST, But A, Lindahl A, et al. Real-life clinical sensitivity of SARS-CoV-2 RT-PCR test in symptomatic patients. PLoS One 2021; 16(5): e0251661.